time for the first decrease in systolic blood pressure to reach the target range
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xiaoning Han, Wei Ma, Bo Wang, Xiang Gu, Guangjun Wang, Ling Lin, Qiufang Lian, Dongna Guo, Xiaoqun Wan, Jiaying Zhu, Wei Guo, Zhenzhong Zhu, Zijing Liang, Dexiong Chen, Anbao Chen, Zhiming Shi, Baofeng Zhu, Anyong Yu, Lishan Yang, Chunhua Zheng, Wenkai Bin, Dapeng Cheng, Yanfen Chai, Jianlong Sheng, Lang Hong, Qiuping Mo, Yu Wang, Lizhen Tang, Shugui Li, Xiwen Zhang, Xiaomei Guo, Ningru Zhang, Yong Huo
J Clin Hypertens (Greenwich) 27(10) e70144
Hypertensive crises require rapid blood pressure control to prevent stroke and myocardial injury. Despite Cleviprex's efficacy, its high cost limits accessibility in China. This Phase III, multicenter, randomized, double-blind study evaluated the efficacy and safety of a generic clevidipine (China's first injectable generic clevidipine emulsion) versus the branded drug Cleviprex in managing hypertensive emergencies and urgencies among Chinese patients. A total of 377 patients of 33 medical centers from December 2021 to December 2022 were randomized, with 189 in the generic clevidipine group and 188 in the control. As a result, 95.6% of patients in the generic clevidipine group and 93.6% in the control achieved the target systolic blood pressure (SBP) reduction within 30 min (rate difference 0.020, 90% CI: -0.019 to 0.060). The mean area under the curve (AUC) of SBP outside the target range within the first hour was comparable between groups (329.8 ± 238.16 in generic clevidipine vs. 347.9 ± 302.79 in control). The median time to first achieve the target range within 30 min was 12.0 min in both groups. The proportion of patients successfully transitioning to oral therapy within 6 h was 93.4% in the generic clevidipine group and 93.6% in the control group. The incidence of drug-related adverse events (AEs) was reported in 50 patients (27.3%) in the generic clevidipine group and in 48 (27.9%) in the control, with no unexpected safety signals. The generic clevidipine demonstrated comparable efficacy and safety to the branded drug, supporting its potential as an effective and accessible therapeutic alternative for acute hypertension management. Trial Registration: chinadrugtrials.org.cn identifier: ChiCTR20212877.
1 个 Figure · 2 个 KM 面板
FIGURE 2 The time for the first decrease in systolic blood pressure to reach the target range within 30 minutes of administration. A The time for the first decrease in systolic blood pressure to reach the target range within 30 minutes of administration in the full analysis set (FAS). B The time for the first decrease in systolic blood pressure to reach the target range within 30 minutes of administration in the per‐protocol set (PPS). * The time was estimated using the Kaplan Meier method, which only included subjects whose SBP dropped to the target range for the first time. ** The median difference between the two groups was estimated using the Hodges Lehmann method, and its 95% confidence interval was calculated using the Hollander normal.
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel B
Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。